ATE352537T1 - Verbindungen, die auf anorganische ionen- rezeptoren wirken - Google Patents

Verbindungen, die auf anorganische ionen- rezeptoren wirken

Info

Publication number
ATE352537T1
ATE352537T1 AT02018228T AT02018228T ATE352537T1 AT E352537 T1 ATE352537 T1 AT E352537T1 AT 02018228 T AT02018228 T AT 02018228T AT 02018228 T AT02018228 T AT 02018228T AT E352537 T1 ATE352537 T1 AT E352537T1
Authority
AT
Austria
Prior art keywords
inorganic ion
compounds acting
compounds
ion receptors
receptor
Prior art date
Application number
AT02018228T
Other languages
English (en)
Inventor
Scott T Moe
Wagenen Bradford C Van
Eric G Delmar
Richard Trovato
Manuel F Balandrin
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Application granted granted Critical
Publication of ATE352537T1 publication Critical patent/ATE352537T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Prostheses (AREA)
  • Eye Examination Apparatus (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Steroid Compounds (AREA)
AT02018228T 1996-05-01 1997-04-30 Verbindungen, die auf anorganische ionen- rezeptoren wirken ATE352537T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1667396P 1996-05-01 1996-05-01

Publications (1)

Publication Number Publication Date
ATE352537T1 true ATE352537T1 (de) 2007-02-15

Family

ID=21778338

Family Applications (3)

Application Number Title Priority Date Filing Date
AT97922601T ATE243186T1 (de) 1996-05-01 1997-04-30 Verbindungen , die auf anorganische ionen- rezeptoren wirken
AT02018228T ATE352537T1 (de) 1996-05-01 1997-04-30 Verbindungen, die auf anorganische ionen- rezeptoren wirken
AT07000764T ATE430123T1 (de) 1996-05-01 1997-04-30 Inorganische am ionen-rezeptor aktive verbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97922601T ATE243186T1 (de) 1996-05-01 1997-04-30 Verbindungen , die auf anorganische ionen- rezeptoren wirken

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07000764T ATE430123T1 (de) 1996-05-01 1997-04-30 Inorganische am ionen-rezeptor aktive verbindungen

Country Status (11)

Country Link
US (3) US5981599A (de)
EP (1) EP0907631B1 (de)
JP (2) JP4117506B2 (de)
AT (3) ATE243186T1 (de)
AU (1) AU731146C (de)
DE (3) DE69739388D1 (de)
DK (1) DK0907631T3 (de)
ES (3) ES2326004T3 (de)
PT (1) PT907631E (de)
TW (1) TW561150B (de)
WO (1) WO1997041090A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
DK0907631T3 (da) * 1996-05-01 2003-09-22 Nps Pharma Inc Uorganiske ionreceptoraktive forbindelser
TW510896B (en) * 1996-07-08 2002-11-21 Kirin Brewery Calcium receptor active compounds, the salt or hydrate thereof, and pharmaceutical composition comprising the same
TR200000443T2 (tr) * 1997-07-09 2000-09-21 Akzo Nobel N.V. Çelatlama maddeleri ve manganik çelatları.
AU1558899A (en) * 1997-11-10 1999-05-31 F. Hoffmann-La Roche Ag Isoquinoline derivatives for use against cns disorders
FR2800735B1 (fr) * 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
US7176243B2 (en) 2000-06-02 2007-02-13 The General Hospital Corporation CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
FR2812875B1 (fr) * 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
ATE385690T1 (de) * 2000-10-12 2008-03-15 Marical Inc Verfahren zur züchtung von nichterwachsenen anadromen fischen
US7101988B2 (en) * 2000-10-12 2006-09-05 Marical, Inc. Polyvalent cation-sensing receptor in Atlantic salmon
US6951739B2 (en) 2000-10-12 2005-10-04 Marical, Inc. Polyvalent cation-sensing receptor in atlantic salmon
US6979558B2 (en) * 2000-10-12 2005-12-27 Marical, Inc. Polyvalent cation-sensing receptor in Atlantic salmon
US6481379B1 (en) * 2000-10-12 2002-11-19 Marical, Llc Methods for raising pre-adult anadromous fish
US6463882B1 (en) 2000-10-12 2002-10-15 Marical, Llc Growing marine fish in freshwater
US6463883B1 (en) 2000-10-12 2002-10-15 Marical, Llc Methods for raising pre-adult anadromous fish
US6979559B2 (en) * 2000-10-12 2005-12-27 Marical, Inc. Polyvalent cation-sensing receptor in atlantic salmon
US6475792B1 (en) 2000-10-12 2002-11-05 Marical, Llc Methods for raising pre-adult anadromous fish
DK1434482T3 (da) * 2001-10-11 2006-08-14 Marical Inc Fremgangsmåder til dyrkning og prægning af fisk ved anvendelse af et lugtstof
US7176322B2 (en) * 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
ES2401769T5 (es) 2003-09-12 2020-07-01 Amgen Inc Formulación de disolución rápida de cinacalcet HCl
EG23529A (en) * 2003-11-05 2006-04-11 Amri Moosa E Al System and method to broadcast the video or tv anddisplaying on pc tv by choosing the required prog ram from the internet
WO2005065050A2 (ja) 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation ２環化合物
HUE028373T2 (en) 2004-05-28 2017-02-28 Mitsubishi Tanabe Pharma Corp Arylalkylamines and processes for their preparation
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
MX2007011153A (es) * 2005-03-17 2007-12-12 Amgen Inc Metodos para reducir la calcificacion.
DK1882684T3 (en) * 2005-05-19 2015-01-05 Astellas Pharma Inc PYRROLIDE INGREDIENTS OR SALTS THEREOF
WO2006127932A2 (en) * 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Purification of cinacalcet
US8415501B2 (en) * 2006-03-23 2013-04-09 Amgen, Inc. Methods and compositions for making and using polymorphs of cinacalcet
AU2007240317B2 (en) * 2006-04-20 2012-11-29 Amgen Inc. Stable emulsion formulations
EP2139462B1 (de) 2007-03-30 2014-01-22 Amgen Inc. Calcimimetische verbindungen zur verwendung bei der behandlung von darmerkrankungen
EP2156846B1 (de) * 2007-05-08 2014-08-13 Ajinomoto Co., Inc. Prophylaktisches oder therapeutisches mittel gegen diarrhö
ES2476391T3 (es) * 2007-10-15 2014-07-14 Amgen Inc. Agentes moduladores de receptor de calcio
WO2010010359A2 (en) * 2008-07-24 2010-01-28 Cilpa Limited A process for the preparation of cinacalcet and its salts
WO2010042642A1 (en) * 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
US8765676B2 (en) 2009-05-27 2014-07-01 Leo Pharma A/S Calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2435400A2 (de) 2009-05-27 2012-04-04 Leo Pharma A/S Neue, den calcium sensing receptor modulierende verbindungen und deren pharmazeutische verwendung
CA2762133A1 (en) * 2009-05-27 2010-12-02 Leo Pharma A/S Calcium-sensing receptor-active compounds
US8946474B2 (en) 2010-06-30 2015-02-03 Leo Pharma A/S Polymorphic form of a calcimimetic compound
JP5968880B2 (ja) 2010-06-30 2016-08-10 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
US20130244995A1 (en) 2010-11-26 2013-09-19 Leo Pharma A/S Calcium-sensing receptor-active compounds
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
EP2643298A1 (de) 2010-11-26 2013-10-02 Leo Pharma A/S Substituierte cyclopentylazine als casr-aktive verbindungen
RU2013128968A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительного рецептора
WO2012120476A1 (en) * 2011-03-10 2012-09-13 Lupin Limited Substituted morpholines as modulators for the calcium sensing receptor
WO2013136288A1 (en) * 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2276618A (en) * 1942-03-17 N-phenylaliphatic bihxdroxithenyl-
CH217009A (fr) * 1940-10-25 1941-09-30 Anonyme Taubert Freres Societe Boîte de montre.
US2930731A (en) * 1952-04-08 1960-03-29 Upjohn Co Bis[beta-(ortho-hydrocarbonoxyphenyl)iso-propyl]amines
BE570596A (de) * 1957-08-26
BE621300A (de) * 1961-08-14
US3262977A (en) * 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
NL293886A (de) * 1962-06-19 1965-04-12 Merck Ag E
US3318952A (en) * 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3459767A (en) * 1965-08-10 1969-08-05 Pfizer & Co C Aminomethylindoles
GB1109924A (en) * 1965-11-29 1968-04-18 Roche Products Ltd Novel substituted diphenylalkyl amines and a process for the manufacture thereof
DE1618005A1 (de) * 1966-09-22 1971-09-09 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen Amino-dihalogen-phenyl-aethylaminen
CH480791A (de) * 1967-01-17 1969-11-15 Ciba Geigy Schädlingsbekämpfungsmittel
GB1263987A (en) * 1969-05-30 1972-02-16 Allen & Hanburys Ltd Phenethylamine derivatives
GB1448437A (en) * 1973-02-24 1976-09-08 Beecham Group Ltd Diphenylpropylamines
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US4000197A (en) * 1973-07-23 1976-12-28 The University Of Iowa Research Foundation Asymmetric synthesis of phenylisopropylamines
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (de) * 1974-03-08 1982-06-04
US4014937A (en) * 1974-08-26 1977-03-29 Pfizer Inc. 3,4-And 3,5-dialkoxyphenethylamines
HU169507B (de) * 1974-09-25 1976-12-28
US3987201A (en) * 1974-12-24 1976-10-19 Eli Lilly And Company Method for treating arrhythmia
US4105602A (en) * 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
JPS5390272A (en) * 1977-01-13 1978-08-08 Sendai Fukusokan Kagaku Kenkiy Method of producing optically active salsolizine
US4608391A (en) * 1977-07-05 1986-08-26 Cornell Research Foundation Inc. Catecholamine derivatives, a process for their preparation and pharmaceutical compositions thereof
US4289787A (en) * 1977-12-19 1981-09-15 Eli Lilly And Company Quaternary ammonium antiarrhythmic drugs
DD144050A5 (de) * 1978-06-05 1980-09-24 Ciba Geigy Ag Verfahren zur herstellung von n-alkylierten aminoalkoholen
DE2825961A1 (de) * 1978-06-14 1980-01-03 Basf Ag Fungizide amine
US4391826A (en) * 1978-07-03 1983-07-05 Eli Lilly And Company Phenethanolamines, compositions containing the same, and method for effecting weight control
CA1145767A (en) * 1978-07-03 1983-05-03 Jack Mills Phenethanolamines, compositions containing the same, and method for effecting weight control
ZA794872B (en) * 1978-09-20 1980-11-26 Schering Corp A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it
FR2436773A1 (fr) * 1978-09-22 1980-04-18 Roussel Uclaf Nouveaux derives du 3-(aminoethyl) phenol et leurs sels, procede de preparation et application a titre de medicaments
US4360511A (en) * 1978-11-29 1982-11-23 Medi-Physics, Inc. Amines useful as brain imaging agents
DD150456A5 (de) * 1979-03-01 1981-09-02 Ciba Geigy Ag Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
DE3061334D1 (en) * 1979-06-16 1983-01-20 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
JPS603387B2 (ja) * 1980-07-10 1985-01-28 住友化学工業株式会社 新規光学活性イミダゾリジン−２−オン誘導体およびその製法
HU183430B (en) * 1981-05-12 1984-05-28 Chinoin Gyogyszer Es Vegyeszet Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride
US4591605A (en) * 1981-11-10 1986-05-27 Research Foundation Of State University Of New York Method and ingestible formulation for inhibiting the secretion of stomach acid
US4658060A (en) * 1982-04-26 1987-04-14 Schering Corporation Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide
DE3225879A1 (de) * 1982-07-10 1984-01-12 Basf Ag, 6700 Ludwigshafen Trans-3-(4'-tert.-butylcyclohexyl-1')-2-methyl-1-dialkyl-aminopropane, ihre herstellung und verwendung als arzneimittel
CA1258454A (en) * 1982-08-10 1989-08-15 Leo Alig Phenethanolamines
US4647446A (en) * 1982-08-18 1987-03-03 The Regents Of The University Of California Rapid brain scanning radiopharmaceutical
JPS5950358A (ja) * 1982-09-14 1984-03-23 Sumitomo Chem Co Ltd 光学活性なカルボン酸をグラフトしたクロマトグラフ充填剤およびそれを用いる鏡像体混合物の分離法
US4677101A (en) * 1983-09-26 1987-06-30 Merck & Co., Inc. Substituted dihydroazepines useful as calcium channel blockers
US4661635A (en) * 1983-11-21 1987-04-28 Mcneilab, Inc. Aralykyl (arylethynyl)aralkyl amines and their use as vasodilators and antihypertensives
US5334628A (en) * 1984-06-09 1994-08-02 Kaken Pharmaceutical Co., Ltd. Amine derivatives, processes for preparing the same and fungicides containing the same
US4587253A (en) * 1984-07-30 1986-05-06 Merck & Co., Inc. Bridged pyridine compounds useful as calcium channel blockers and analgesics
US4609494A (en) * 1985-02-21 1986-09-02 Merck & Co., Inc. 5-acetyl-3,4,5,6-tetrahydro-4-oxo-2,6-methano-2H-1,3,5-benzothiazocine(benzodiazocine)-11-carboxylates useful as calcium channel blockers
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
GB8522186D0 (en) * 1985-09-06 1985-10-09 Erba Farmitalia Cycloalkyl-substituted 4-aminophenyl derivatives
DE3541181A1 (de) * 1985-11-21 1987-05-27 Basf Ag Propylamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US4675321A (en) * 1986-02-07 1987-06-23 Merck & Co., Inc. Substituted pyrimidines useful as calcium channel blockers
US5034514A (en) * 1986-03-17 1991-07-23 Cetus Corporation Novel cross-linking agents
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US4808718A (en) * 1986-05-06 1989-02-28 Merck & Co., Inc. Fused polycyclic and bridged compounds useful as calcium channel blockers
HU200591B (en) * 1986-07-11 1990-07-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new diphenyl propylamine derivatives and pharmaceutical compositions comprising such compounds
IL83163A (en) * 1986-07-18 1991-06-10 Erba Carlo Spa Cycloalkyl-substituted 4-pyridyl derivatives,their preparation and pharmaceutical compositions containing them
HU207280B (en) * 1986-09-25 1993-03-29 Chinoin Gyogyszer Es Vegyeszet Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them
US5064657A (en) * 1986-10-20 1991-11-12 University Of Utah Spider toxins and methods for their use as blockers of amino acid receptor function
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
EP0270376B1 (de) * 1986-12-04 1992-09-30 Asahi Kasei Kogyo Kabushiki Kaisha Vom Calcitonin-Gen abgeleitete Peptidderivate
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US4916145A (en) * 1987-07-10 1990-04-10 Hoffmann-La Roche Inc. Substituted n-[(pyridyl)alkyl]aryl-carboxamide
ATE128359T1 (de) * 1988-01-11 1995-10-15 Amylin Pharmaceuticals Inc Behandlung von diabetes mellitus typ 2.
US5001251A (en) * 1988-01-15 1991-03-19 E. R. Squibb & Sons, Inc. Optical resolution of DL-3-acylthio-2-methylpropanoic acid
FI904827A7 (fi) * 1988-04-04 1990-10-01 The Salk Inst Biotechnology/ Kalsiumkanavakoostumuksia ja -menetelmiä
US5082837A (en) * 1988-06-28 1992-01-21 Merrell Dow Pharmaceuticals Lactamimides as calcium antagonists
US4925873A (en) * 1988-09-01 1990-05-15 E. R. Squibb & Sons, Inc. Method of treating skin injuries using thromboxane A2 receptor antagonists
JPH02200658A (ja) * 1989-01-28 1990-08-08 Kumiai Chem Ind Co Ltd Ｎ―（置換）ベンジルカルボン酸アミド誘導体及び除草剤
US5011834A (en) * 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
DD298412A5 (de) * 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
IL94963A0 (en) * 1989-07-03 1991-06-10 Univ New York Use of polyamines as ionic-channel regulating agents
GB8915712D0 (en) * 1989-07-08 1989-08-31 Macintyre Iain Medical treatment
US5021599A (en) * 1989-08-31 1991-06-04 Serpentix Conveyor Corporation Redox-responsive anion receptors
US5053337A (en) * 1989-10-30 1991-10-01 Neurogenetic Corporation DNA encoding an α2B -adrenergic receptor
AU658134B2 (en) * 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
JP2818958B2 (ja) * 1990-02-23 1998-10-30 塩野義製薬株式会社 ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法
US5096908A (en) * 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
WO1992007829A1 (en) * 1990-11-02 1992-05-14 The Upjohn Company Indole-3-methanamines useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
DE69233479T2 (de) * 1991-02-08 2006-03-16 Scion Pharmaceuticals, Inc., Medford Substituierte Guanidine und Derivate hiervon als Modulatoren der Freisetzung von Neurotransmittern und neue Methode zur Identifizierung von Inhibitoren der Neurotransmitter-Freisetzung
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
DK0508307T3 (da) * 1991-04-08 1995-12-27 Sumitomo Chemical Co Optisk aktive sekundære aminforbindelser, fremgangsmåde til fremstilling af en optisk aktiv sekundær aminforbindelse og fremgangsmåde til fremstilling af en optisk aktiv carboxylsyre ved anvendelse af denne forbindelse
CN1065857A (zh) * 1991-04-16 1992-11-04 北京农业大学 光活性1,1′-联萘-2,2′-二酚的合成方法
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
DK0724561T3 (da) * 1991-08-23 2004-06-28 Nps Pharma Inc Calciumreceptoraktive arylalkylaminer
ES2256370T3 (es) * 1991-08-23 2006-07-16 Nps Pharmaceuticals, Inc. Moleculas activas para el receptor de calcio.
FI942187A7 (fi) * 1991-11-12 1994-05-11 Pfizer Asyklisiä etyleenidiamiinijohdannaisia aine P-reseptoriantagonisteina
JPH07502524A (ja) * 1991-12-30 1995-03-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ α−置換ベンゼンメタナミン誘導体
WO1993015044A1 (en) * 1992-01-29 1993-08-05 Smithkline Beecham Corporation N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as tnf and pde iv inhibitors
EP0637237B1 (de) * 1993-02-23 2004-05-19 Brigham And Women's Hospital, Inc. Calciumrezeptoraktive moleküle
GB9326403D0 (en) * 1993-12-24 1994-02-23 Oxford Asymmetry Ltd Improvements in or relating to chiral syntheses
US5504253A (en) * 1994-07-15 1996-04-02 Nps Pharmaceuticals, Inc. Amine preparation
EP1203761B1 (de) * 1994-10-21 2005-01-19 Nps Pharmaceuticals, Inc. Kalzium-Rezeptor aktive Verbindungen
US5648541A (en) * 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
DK0907631T3 (da) * 1996-05-01 2003-09-22 Nps Pharma Inc Uorganiske ionreceptoraktive forbindelser

Also Published As

Publication number Publication date
ATE243186T1 (de) 2003-07-15
JP4117506B2 (ja) 2008-07-16
DE69722934D1 (de) 2003-07-24
DE69739388D1 (de) 2009-06-10
US5981599A (en) 1999-11-09
ATE430123T1 (de) 2009-05-15
ES2326004T3 (es) 2009-09-28
JP2000509395A (ja) 2000-07-25
US6710088B2 (en) 2004-03-23
DE69737303D1 (de) 2007-03-15
TW561150B (en) 2003-11-11
WO1997041090A1 (en) 1997-11-06
US6342532B1 (en) 2002-01-29
DE69737303T2 (de) 2007-08-30
AU731146B2 (en) 2001-03-22
PT907631E (pt) 2003-10-31
HK1102806A1 (en) 2007-12-07
DK0907631T3 (da) 2003-09-22
AU2822997A (en) 1997-11-19
ES2201300T3 (es) 2004-03-16
ES2280460T3 (es) 2007-09-16
AU731146C (en) 2005-02-03
HK1051995A1 (en) 2003-08-29
JP2008115184A (ja) 2008-05-22
EP0907631B1 (de) 2003-06-18
EP0907631A1 (de) 1999-04-14
JP4431609B2 (ja) 2010-03-17
DE69722934T2 (de) 2004-05-27
US20030008876A1 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
ATE243186T1 (de) Verbindungen , die auf anorganische ionen- rezeptoren wirken
WO1996012697A3 (en) Calcium receptor-active compounds
ATE264292T1 (de) Kalzium - receptor aktive arylalkylamine
BR9510486A (pt) Compostos moduladores de receptores de esteróide e métodos
IL120424A0 (en) Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
DE69709710D1 (de) Elektrochrome oder photoelektrochrome vorrichtung
YU59098A (sh) Derivati spiro-piperidina, postupak njihovog dobijanja, njihova upotreba u proizvodnji leka korisnog za lečenje ili prevenciju bolova, upalnih procesa, migrene, povraćanja i postherpetične neuralgije i farmaceutski sastav koji ih sadrži
ES2168650T3 (es) Compuestos y metodos moduladores de receptores de androgenos.
DE69600113D1 (de) Vorrichtung zum Vernebeln von Mineralwasser
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
NZ503033A (en) Inhibition of complement activation using anti-properdin agents
FR2773075B1 (fr) Utilisation d'activateurs de ppar-gamma en dermatologie
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
DE69426033D1 (de) Für die alpha-1e untereinheit des menschlichen kalziumkanals kodierende dna
PT951282E (pt) Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2
WO2003014321A3 (en) Compositions and methods for modulation of darpp-32 phosphorylation
DE69736669D1 (de) Zelladhäsionsinhibitoren
NO994850L (no) Farmakologiske midler
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
PT628033E (pt) Derivados de benzodiazepina uteis como antagonistas dos receptores-cck
YU41998A (sh) Tetrahidrobetakarbolinska jedinjenja
ATE239823T1 (de) Verffahren und vorrichtung zur steuerung der papiereigenschaften
ATE354802T1 (de) Methoden zum screening knochenmorphogenetishemimetika
DK1506313T3 (da) Fremgangsmåder til screening af modulatorer af den mitokondrielle NAD-afhængige deacetylase SIRT3
EP1258471A3 (de) Verbindungen, die auf anorganische Ionen-Rezeptoren wirken

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties